Navigation Links
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
Date:10/19/2010

elating to OncoGenex' operations and financial performance and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for second fiscal quarter of 2010 and the preliminary prospectus supplement to be filed with the SEC.  The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
2. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
3. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. OncoGenex Reports Second Quarter Financial Results
6. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
(Date:4/24/2015)... 24, 2015  Navitas Life Sciences is delighted to announce ... Clinical and Regulatory Services. Shalabh is a proven leader in ... CEO of Kinapse, as well as a Strategy consultant at ... - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... "I am delighted to welcome Shalabh into this critical role ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... 28, 2011 Nature,s Bioceuticals, a wholly owned subsidiary ... billion market chronic obstructive pulmonary disease market (COPD) with ... This all natural, non-synthetic, medicine was developed for the ... which are Emphysema and Chronic Bronchitis. We believe that ...
... at the Georgia Institute of Technology have developed a ... a key ingredient found in many explosives. ... on paper or paper-like material using standard inkjet technology, ... to the presence of explosives, such as improvised explosive ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... to Halozyme,s clinical stage drug, pegylated rHuPH20 (PEGPH20). The ... on "Molecular Markers in Cancer", taking place October 27-29 ...
Cached Biology Technology:Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 2Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 3Low-cost paper-based wireless sensor could help detect explosive devices 2Low-cost paper-based wireless sensor could help detect explosive devices 3Low-cost paper-based wireless sensor could help detect explosive devices 4Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Researchers from the University of Bath are embarking on ... reduce the number of animal experiments used to study ... Subramanian, from the University,s Department of Biology & Biochemistry, ... to study this debilitating neurological disease, greatly reducing the ...
... one another in a variety of ways: behavior, body patterns, ... Ecological Society of America,s annual meeting, to be held August ... for exchanging information among living things. Bugs pretending ... classic example of a mutualism, or a mutually beneficial relationship ...
... (August 4, 2009) Divers who held their breath for ... signal brain damage, according to a new study from the ... the protein, S100B, was transient and leaves open the question ... the long term. "The results indicate that prolonged, ...
Cached Biology News:New stem cell research could reduce number of animal experiments 2Animal and plant communication at the ESA Annual Meeting 2Animal and plant communication at the ESA Annual Meeting 3Animal and plant communication at the ESA Annual Meeting 4Holding breath for several minutes elevates marker for brain damage 2Holding breath for several minutes elevates marker for brain damage 3Holding breath for several minutes elevates marker for brain damage 4
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... effectively seals labware. Waterproof, moisture-proof film ... materials. Can be folded repeatedly and ... Stretched lengthwise at 21C (70F), wrapping ... tension is removed, film only partially ...
Biology Products: